Takeda's TAK-881 Matches HYQVIA in Pivotal Phase 2/3 Trial While Halving the Infusion Volume for Primary Immunodeficiency Patients

Overview

Takeda announced on May 4 that TAK-881-3001, a pivotal Phase 2/3 trial of its investigational subcutaneous immunoglobulin in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint by demonstrating pharmacokinetic comparability with HYQVIA, the company’s existing facilitated subcutaneous IG product, according to BioSpace. The new formulation delivered the same dose of antibodies in half the infusion volume, with secondary endpoints showing comparable safety, efficacy, and tolerability against the established comparator.

What We Know

TAK-881 is a 20% subcutaneous immunoglobulin facilitated with recombinant human hyaluronidase, while HYQVIA is the 10% formulation Takeda already markets, as described by BioSpace. Doubling the protein concentration is what allows the same therapeutic dose to be delivered in half the liquid volume.

The primary endpoint was IgG exposure equivalence. According to BioSpace, TAK-881 produced a geometric mean ratio of 99.67% versus HYQVIA, with a 90% confidence interval of 95.10% to 104.46% — well within the bioequivalence margins typical for such studies. Fierce Biotech reported the same 99.67% ratio for the areas under the concentration-time curves over one dosing interval.

The study enrolled adults and pediatric patients aged 2 years and older. As BioSpace detailed, participants 16 and older were randomized in an open-label cross-over arm to receive TAK-881 followed by HYQVIA, or HYQVIA followed by TAK-881, at the same dose and dosing interval for up to 51 weeks. Participants aged 2 to under 16 received TAK-881 only for up to 27 weeks in a single-arm study part.

Beyond pharmacokinetic equivalence, secondary endpoints showed safety, efficacy, and tolerability profiles comparable to HYQVIA, with the new formulation reducing infusion duration while maintaining flexible, up-to-once-monthly dosing, BioSpace reported. Fierce Biotech added that infection rates and immune protection were also comparable.

Kristina Allikmets, MD, PhD, Senior Vice President and Head of Plasma Derived Therapies R&D at Takeda, said the results showed “the pharmacokinetic profile of TAK-881 was comparable to HYQVIA, an established IG standard of care in patients with PID, while offering the potential advantages of fewer injection sites, a flexible treatment schedule and shorter infusion times,” per BioSpace. Principal investigator Richard L. Wasserman, MD, PhD, framed the patient stakes in the same release: “Patients needing lifelong IG therapy for PID experience a significant burden of care. Improving the administration process can diminish the burden of care by substantively impacting the treatment experience.”

Regulatory Path

Takeda said it expects to submit TAK-881 to regulatory authorities in the United States, European Union, and Japan in fiscal year 2026, according to BioSpace. Fierce Biotech noted that the company’s fiscal 2026 ends in March 2027, giving a roughly ten-month window for the three filings.

What We Don’t Know

The topline release did not disclose specific tolerability metrics — local reaction rates at infusion sites, dropout rates, or details of any adverse events — leaving full safety characterization to a future presentation or publication. Pricing relative to HYQVIA, market launch timing if approved, and the structure of any clinical-comparison data Takeda plans to submit to payers remain unstated.

The trial design also does not directly answer whether the volume reduction translates into measurable improvements in adherence or quality of life over the long term. Those endpoints would typically require a separate observational or post-marketing study.